Cargando…

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

BACKGROUND: High expression of the metabolic enzyme arginase-2 (ARG2) by cancer cells, regulatory immune cells, or cells of the tumor stroma can reduce the availability of arginine (L-Arg) in the tumor microenvironment (TME). Depletion of L-Arg has detrimental consequences for T cells and leads to T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weis-Banke, Stine Emilie, Lisle, Thomas Landkildehus, Perez-Penco, Maria, Schina, Aimilia, Hübbe, Mie Linder, Siersbæk, Majken, Holmström, Morten Orebo, Jørgensen, Mia Aaboe, Marie Svane, Inge, Met, Özcan, Ødum, Niels, Madsen, Daniel Hargbøl, Donia, Marco, Grøntved, Lars, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628693/ https://www.ncbi.nlm.nih.gov/pubmed/36316062 http://dx.doi.org/10.1136/jitc-2022-005326

Ejemplares similares

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8(+)T cells
por: Lie-Andersen, Olivia, et al.
Publicado: (2023)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade
por: Hübbe, Mie Linder, et al.
Publicado: (2020)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone
por: Præstholm, Stine M., et al.
Publicado: (2020)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Collagen density regulates the activity of tumor-infiltrating T cells
por: Kuczek, Dorota E., et al.
Publicado: (2019)

High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss
por: Siersbæk, Majken, et al.
Publicado: (2017)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
por: Ballantyne, Laurel L., et al.
Publicado: (2016)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Insulin signaling and reduced glucocorticoid receptor activity attenuate postprandial gene expression in liver
por: Kalvisa, Adrija, et al.
Publicado: (2018)

Synthetic DNA Delivery of an Engineered Arginase Enzyme Can Modulate Specific Immunity In Vivo
por: Khoshnejad, Makan, et al.
Publicado: (2020)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Inflammation induced PD-L1-specific T cells
por: Munir, Shamaila, et al.
Publicado: (2019)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Cerebral Changes Occurring in Arginase and Dimethylarginine Dimethylaminohydrolase (DDAH) in a Rat Model of Sleeping Sickness
por: Amrouni, Donia, et al.
Publicado: (2011)

Arginase and pulmonary diseases
por: Maarsingh, Harm, et al.
Publicado: (2008)

Calbindin 2-specific deletion of arginase 2 preserves visual function after optic nerve crush
por: Zaidi, Syed A. H., et al.
Publicado: (2023)

FOXP3-specific immunity
por: Andersen, Mads Hald
Publicado: (2013)

Peak shifts and extinction under sex-specific selection
por: De Lisle, Stephen P.
Publicado: (2021)

Arginase and Arginine Dysregulation in Asthma
por: Benson, Renée C., et al.
Publicado: (2011)

Endothelial arginase II and atherosclerosis
por: Ryoo, Sungwoo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8csv6nsho4ufgifmsg3gbvg546